Skip to main content

Menu

Select a tool from the sidebar

Create your free account now!

Sign in to customize and use tools on the sidebar.

Sign InCreate free account
Pharma Mar, S.A. logo
PHM.MC
Pharma Mar, S.A.
13:12:06
69.15 €
0.0000 (%0.00)
Previous Close: 69.35
Day Low₺68.7
Day High₺69.7
Bid
Ask
Overview
Technicals
Financial Statements
Comments
Archive

PHM.MC: Pharma Mar, S.A. Financials

Pharma Mar, S.A. Income Statement

Total revenue
Net income
Gross margin TTM
94.46%
Operating margin TTM
18.19%
Net profit margin TTM
33.87%
Return on investment TTM
29.78%
Period end31/12/202531/12/202431/12/202331/12/2022
Total revenue221,390,000174,855,000158,153,000196,343,000
Operating income40,276,0006,468,000-3,827,00044,071,000
Net income74,986,00026,125,0001,137,00049,356,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Total revenue221,390,000174,855,000158,153,000196,343,000
Cost of revenue12,260,0008,183,0009,613,00013,639,000
Gross profit209,130,000166,672,000148,540,000182,704,000
Research and development expenses95,191,000103,502,00099,302,00083,449,000
General and administrative expenses-2,341,000-2,853,00018,263,00019,022,000
Selling and marketing expenses199,000174,00023,542,00024,219,000
Selling, general and administrative expenses-2,142,000-2,679,00041,805,00043,241,000
Other expenses75,805,00059,381,00011,260,00011,579,000
Operating expenses168,854,000160,204,000152,367,000138,269,000
Cost and expenses181,114,000168,387,000161,980,000151,908,000
Net interest income650,0003,196,0001,687,000-1,501,000
Interest income3,109,0005,665,0004,103,000875,000
Interest expense2,459,0002,469,0002,416,0002,376,000
Depreciation and amortization8,020,0006,771,0005,756,0005,900,000
EBITDA48,296,00021,225,0004,549,00052,066,000
EBIT40,276,00014,454,000-1,207,00046,166,000
Non-operating income (excl. interest)0-7,986,000-2,620,000-2,095,000
Operating income40,276,0006,468,000-3,827,00044,071,000
Total other income/expenses (net)19,375,0005,517,000204,000-281,000
Income before tax59,651,00011,985,000-3,623,00043,790,000
Income tax expense-15,335,000-14,140,000-4,760,000-5,566,000
Net income from continuing operations74,986,00026,125,0001,137,00049,356,000
Net income from discontinued operations0000
Other adjustments to net income0000
Net income74,986,00026,125,0001,137,00049,356,000
Net income deductions0000
Bottom line net income74,986,00026,125,0001,137,00049,356,000
EPS410.06353
Diluted EPS410.06353
Weighted average shares outstanding17,210,00017,539,00017,900,00018,050,000
Weighted average diluted shares outstanding17,210,00017,562,00017,916,00018,063,000

Pharma Mar, S.A. Balance Sheet

Total assets
Total liabilities & equity
Liquidity ratio MRQ
—
Current ratio MRQ
—
Long-term debt / assets MRQ
35,552,000%
Total debt / assets MRQ
—
Period end31/12/202531/12/202431/12/202331/12/2022
Total assets395,081,000349,644,000340,520,000393,259,000
Total liabilities143,248,000141,285,000147,082,000170,302,000
Total equity251,833,000208,359,000193,438,000222,957,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Cash and cash equivalents17,817,00063,239,00060,024,000149,813,000
Short-term investments149,406,00091,288,000102,538,00032,607,000
Cash and short-term investments167,223,000154,527,000162,562,000182,420,000
Net receivables60,595,00034,677,00027,554,00029,324,000
Accounts receivable39,409,00034,270,00027,203,00028,972,000
Other receivables21,186,000407,000351,000352,000
Inventory54,101,00050,886,00039,289,00027,746,000
Prepaid expenses1,496,0002,824,0002,917,0005,980,000
Other current assets07,334,00020,280,00029,713,000
Total current assets283,415,000250,248,000252,602,000275,183,000
Property, plant and equipment (net)60,150,00059,080,00047,607,00034,715,000
Goodwill0000
Intangible assets3,547,0001,000,0001,935,0002,589,000
Goodwill and intangible assets3,547,0001,000,0001,935,0002,589,000
Long-term investments1,423,000-88,829,0006,062,00016,791,000
Tax assets46,546,00036,012,00031,469,00030,529,000
Other non-current assets092,133,0001,548,00033,452,000
Total non-current assets111,666,00099,396,00088,621,000118,076,000
Other assets00-703,0000
Total assets395,081,000349,644,000340,520,000393,259,000
Total payables57,355,00038,650,00029,174,00027,492,000
Accounts payable54,339,00038,650,00029,174,00027,492,000
Other payables3,016,000000
Accrued expenses010,216,00012,391,00010,439,000
Short-term debt11,026,0007,966,00012,825,00013,125,000
Capital lease obligations (current)1,706,0001,881,0001,980,0001,608,000
Tax payables02,333,00000
Deferred revenue4,647,0005,383,00025,949,00026,112,000
Other current liabilities19,144,00034,197,00039,518,00044,656,000
Total current liabilities93,878,00082,694,00095,888,00097,320,000
Long-term debt35,552,00039,865,00027,036,00025,883,000
Capital lease obligations (non-current)1,131,0001,363,0001,828,0002,014,000
Deferred revenue (non-current)12,637,00017,169,00022,137,00044,899,000
Deferred tax liabilities (non-current)00703,000470,000
Other non-current liabilities50,000194,000896,000186,000
Total non-current liabilities49,370,00058,591,00051,897,00072,982,000
Other liabilities00-703,0000
Capital lease obligations2,837,0003,244,0003,808,0003,622,000
Total liabilities143,248,000141,285,000147,082,000170,302,000
Treasury stock-38,719,000-30,827,000-31,091,000-15,865,000
Preferred stock0010
Common stock10,800,00010,933,00011,013,00011,013,000
Retained earnings233,825,000168,379,000142,223,000156,512,000
Additional paid-in capital45,909,00059,858,00071,278,00071,278,000
Accumulated other comprehensive income/loss18,00016,00014,99919,000
Other stockholders' equity0000
Total stockholders' equity251,833,000208,359,000193,438,000222,957,000
Total equity251,833,000208,359,000193,438,000222,957,000
Minority interest0000
Total liabilities and total equity395,081,000349,644,000340,520,000393,259,000
Total investments150,829,0002,459,000108,600,00049,398,000
Total debt49,415,00051,075,00043,669,00042,630,000
Net debt31,598,000-12,164,000-16,355,000-107,183,000

Pharma Mar, S.A. Cash Flow Statement

Cash from operations
Cash from investing
Cash flow / share TTM
—
Revenue / share TTM
—
Operating cash flow TTM
—
Period end31/12/202531/12/202431/12/202331/12/2022
Cash from operations53,130,0006,027,000-13,446,00038,321,000
Cash from investing-60,788,0001,033,000-43,048,00010,878,000
Cash from financing-36,524,000-5,350,000-32,137,000-13,370,000
Net change in cash-45,422,0003,215,000-89,789,00036,465,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Net income59,651,00011,985,0001,137,00043,790,000
Depreciation and amortization8,020,0006,773,0005,756,0005,900,000
Deferred income tax0000
Stock-based compensation320,0000297,000393,000
Change in working capital-8,897,000-31,746,000-34,923,000-28,220,000
Accounts receivable-4,993,000-7,319,0001,783,00021,612,000
Inventory-2,133,000-12,680,000-11,542,000-17,210,000
Accounts payable-12,757,00011,232,0001,825,0001,786,000
Other working capital10,986,000-22,979,000-26,989,000-34,408,000
Other non-cash items-5,964,00019,015,00014,287,00016,458,000
Net cash from operating activities53,130,0006,027,000-13,446,00038,321,000
Investments in property, plant and equipment-6,462,000-15,015,000-15,956,000-8,852,000
Acquisitions (net)00011,000
Purchases of investments-342,577,000-351,475,000-314,328,000-219,199,000
Sales/maturities of investments286,267,000367,130,000287,236,000238,918,000
Other investing activities1,984,000393,00000
Net cash from investing activities-60,788,0001,033,000-43,048,00010,878,000
Net debt issuance-1,463,0008,908,000-1,153,000-8,658,000
Long-term net debt issuance-1,463,0008,908,000-1,153,000-8,658,000
Short-term net debt issuance0000
Net stock issuance-18,250,000215,000-37,901,0007,049,000
Net common stock issuance-18,250,000215,000-19,295,0007,049,000
Common stock issuance15,870,00018,911,00018,606,00057,227,000
Common stock repurchased-34,120,000-18,696,000-37,901,000-50,178,000
Net preferred stock issuance00-18,606,0000
Net dividends paid-13,949,000-11,420,000-11,689,000-11,761,000
Common dividends paid-13,949,000-11,420,000-11,689,000-11,761,000
Preferred dividends paid0000
Other financing activities-2,862,000-3,053,00018,606,0000
Net cash from financing activities-36,524,000-5,350,000-32,137,000-13,370,000
Effect of FX changes on cash-1,240,0001,505,000-1,158,000636,000
Net change in cash-45,422,0003,215,000-89,789,00036,465,000
Cash at end of period17,817,00063,239,00060,024,000149,813,000
Cash at beginning of period63,239,00060,024,000149,813,000113,348,000
Operating cash flow53,130,0006,027,000-13,446,00038,321,000
Capital expenditure-9,379,000-15,510,000-15,956,000-8,852,000
Free cash flow43,751,000-9,483,000-29,402,00029,469,000
Income taxes paid0000
Interest paid0000